Limited coverage drugs – fluticasone furoate in combination with umeclidinium and vilanterol

Last updated on January 17, 2024
Generic name

fluticasone furoate-umeclidinium-vilanterol


fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg


dry powder for oral inhalation

Special Authority criteria

Approval period

Diagnosis of moderate to very severe1 chronic obstructive pulmonary disease (COPD) where spirometry measures are as follows:

  • A post-bronchodilator fixed ratio of forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 0.70


  • A post-bronchodilator FEV1 < 80% predicted


Who have a history of exacerbations as follows:

  • History of ≥ 2 moderate exacerbations defined as requiring a prescribed antibiotic and/or using systemic glucocorticoids in the previous 12 months


  • History of ≥ 1 severe exacerbation defined as requiring a hospital admission or emergency department visit in the previous 12 months


Inadequate response after a minimum 6-month trial of either

  • a combination of long-acting muscarinic receptor antagonist (LAMA) and long-acting beta agonist (LABA)


  • a combination of inhaled corticosteroids (ICS) and LABA



  • Moderate to very severe COPD is defined as follows:
    • Moderate COPD is defined as 50% ≤ FEV1 < 80% predicted
    • Severe COPD is defined as 30% ≤ FEV1 < 50% predicted
    • Very severe COPD is defined as FEV1 < 30% predicted

Practitioner exemptions

  • Respirologists are invited to apply for a Collaborative Prescribing Agreement (CPA).
  • Respirologists who already have a CPA for budesonide-gylcopyrronium-formoterol (Breztri Aerosphere) automatically have a CPA for Trelegy Ellipta. 

Special notes

  • In remote areas, where spirometry access is limited, spirometry measurements are to be provided within 6 months.

Special Authority request form(s)